About 64 results
Open links in new tab
  1. Recursion's Drug Discovery Pipeline | Recursion

    Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high …

  2. Pioneering AI Drug Discovery | Recursion

    All of our results feed back into our drug discovery and drug development platform – the Recursion Operating System – in a continuously improving feedback loop.

  3. Recursion Pharmaceuticals, Inc. - Recursion and Exscientia Enter ...

    Aug 8, 2024 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, …

  4. Recursion Reports Third Quarter 2025 Financial Results and …

    Oct 9, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New …

  5. 28th Annual Needham Growth Conference - ir.recursion.com

    The Investor Relations website contains information about Recursion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

  6. Recursion Reports Second Quarter 2025 Financial Results and …

    Jun 30, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New …

  7. David Hallett, Ph.D. - recursion.com

    Dave Hallett comes to Recursion after approximately 5 years as the Chief Scientific Officer and Interim CEO of Exscientia. David Hallett, Ph.D., is an experienced “drug hunter” with over 20 …

  8. ir.recursion.com

    ir.recursion.com

  9. Matchmaker - portfolio.recursion.com

    Dive into an interactive experience with our pipeline, partners and models.

  10. Recursion Reports First Quarter 2025 Financial Results and …

    Mar 31, 2025 · In total, the partnership has generated $130 million of cash inflows (including an upfront payment) to Recursion to date. Recursion’s collaboration within Neuroscience and a GI …